US Stock MarketDetailed Quotes

CTLT Catalent

Watchlist
  • 55.960
  • +0.180+0.32%
Close Apr 17 16:00 ET
  • 56.340
  • +0.380+0.68%
Post 17:18 ET
10.13BMarket Cap-7793P/E (TTM)

About Catalent Company

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Company Profile

SymbolCTLT
Company NameCatalent
Listing DateJul 31, 2014
Issue Price20.50
Founded1933
CEOMr. Alessandro Maselli
MarketNYSE
Employees17800
Securities TypeOrdinary Shares
Fiscal Year Ends06-30
Address14 Schoolhouse Road
CitySomerset
ProvinceNew Jersey
CountryUnited States of America
Zip Code08873
Phone1-732-537-6200

Company Executives

  • Name
  • Position
  • Salary
  • Alessandro Maselli
  • Chief Executive Officer and President
  • 6.58M
  • Michael J. Hatzfeld, Jr
  • Vice President and Chief Accounting Officer
  • --
  • Lisa Evoli
  • Senior Vice President and Chief Human Resources Officer
  • --
  • Joseph A. Ferraro
  • Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
  • --
  • Matti Masanovich
  • Senior Vice President and Chief Financial Officer
  • --
  • Karen Murphy Santiago
  • Vice President and Business Transformation & Integration Officer
  • --
  • Scott Gunther
  • Senior Vice President, Quality and Regulatory Affairs
  • --
  • Ricky Hopson
  • President, Division Head of BioProduct Delivery and Chief of Staff
  • 972.31K
  • Dr. Aristippos Gennadios
  • Group President, Pharma and Consumer Health
  • 3.80M
  • John J. Greisch
  • Executive Chairman of the Board
  • 400.86K
  • David McErlane
  • Group President, Biologics
  • --
  • Frank D’Amelio
  • Independent Director
  • --
  • Gregory T. Lucier
  • Independent Director
  • 387.61K
  • Michelle R. Ryan
  • Independent Director
  • --
  • Steven K. Barg
  • Independent Director
  • --
  • Rolf A. Classon
  • Independent Director
  • 384.95K
  • Stephanie S. Okey, M.S.
  • Independent Director
  • --
  • Michael J. Barber
  • Independent Director
  • 374.95K
  • J. Martin Carroll
  • Independent Director
  • 426.36K
  • Jack L. Stahl
  • Lead Independent Director
  • 395.11K
  • Dr. Donald E. Morel,Jr
  • Independent Director
  • 384.95K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg